https://www.selleckchem.com/pr....oducts/fasoracetam-n
Although the role of obesity-induced metabolic abnormalities in impaired lung function is well-established, the risk of impaired lung function among obese individuals without metabolic abnormalities, referred to metabolically-healthy obesity (MHO), is largely unexplored. Therefore, we evaluated the impact of MHO on lung function in a large health-screening cohort. 114,143 subjects (65,342 men, mean age and BMI 39.6 years and 23.6) with health examinations in 2019 were divided into four groups as follows metabolically healthy